Science’s COVID-19 reporting is supported by the Pulitzer Center.
The U.S. Food and Drug Administration (FDA) today revoked its emergency use authorization (EUA) for hydroxychloroquine sulfate (HCQ) and chloroquine phosphate (CQ) to treat COVID-19. The two antimalaria drugs, touted by President Donald Trump and others as potential game-changers in tackling the new coronavirus that causes COVID-19, have failed in recent randomized controlled clinical trials to prevent disease in newly infected people or treat those with symptoms. In April, former FDA leaders decried the agency’s decision to authorize emergency use of the drugs, asserting it was based on political pressure, not scientific evidence.
“I’m glad to see FDA remediate an action that was a significant departure from its science-based approach. I hope this is a step forward to FDA regaining its independence and for making decisions that are based on science and the public interest,” says Luciana Borio, a former FDA acting chief scientist who directed medical and biodefense preparedness for Trump’s National Security Council.